DelveInsight’s “Congenital Adrenal Hyperplasia Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Congenital Adrenal Hyperplasia (CAH), historical and forecasted epidemiology, as well as CAH therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Get a Free sample for the Congenital Adrenal Hyperplasia Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
Some of the Key Facts of the Congenital Adrenal Hyperplasia Market Report:
- In July 2026, Neurocrine Biosciences initiated a Phase 2 study evaluating crinecerfont’s safety and tolerability in pediatric patients aged three months to under four years with classic CAH, conducted under an FDA Pediatric Written Request to support a planned supplemental NDA extending the approved indication to younger infants.
- In May 2026, Neurocrine Biosciences presented two-year data from the CRENESSITY study showing durable hormone control, significant reductions in elevated androstenedione, meaningful reductions in daily glucocorticoid exposure, and improvements in bone age maturation and growth velocity in pediatric CAH patients.
- The total Congenital Adrenal Hyperplasia market size in 2023 was more than USD 20 million across the 7MM, expected to grow at a CAGR of approximately 40% during the forecast period, 2020–2034.
- The US accounted for the highest prevalent cases of CAH in the 7MM in 2023, with approximately 32,000 cases, representing around 50% of total 7MM prevalent cases, a share expected to increase through the forecast period.
- CAH predominantly affects males in the US, with approximately 19,000 males diagnosed compared to 13,000 females in 2023, and individuals over the age of 18 represented the most affected age group in the 7MM, with roughly 36,000 cases in 2020 projected to reach approximately 50,000 by 2034.
- Key Congenital Adrenal Hyperplasia Companies: Neurocrine Biosciences, Crinetics Pharmaceuticals, Lundbeck, Spruce Biosciences, BridgeBio, and others.
- By 2034, BBP-631 is expected to overtake steroids as the largest revenue-generating therapy in the US CAH market, reflecting a broader shift toward gene therapy and glucocorticoid-independent treatment approaches.
Congenital Adrenal Hyperplasia Overview
Congenital Adrenal Hyperplasia is a rare group of inherited autosomal recessive disorders that disrupt adrenal hormone production, most commonly due to 21-hydroxylase deficiency, which accounts for approximately 95% of all CAH cases. Classical CAH can result in life-threatening adrenal crises or atypical genital development, while non-classical CAH tends to present with milder symptoms later in life, such as early puberty, hirsutism, and fertility issues. Since the 1950s, glucocorticoids have remained the cornerstone of management, though lifelong steroid therapy carries significant side-effect burden, driving strong interest in mechanistically distinct emerging therapies.
To know in detail about the CAH market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Congenital Adrenal Hyperplasia Market Forecast
Congenital Adrenal Hyperplasia Epidemiology
The epidemiology section of the report provides insights into the historical, current, and forecasted epidemiology trends across the seven major markets from 2020 to 2034. It draws on numerous studies and the views of key opinion leaders to explain current and forecasted trends, and it also details the diagnosed patient pool along with the assumptions used to project future trends.
Congenital Adrenal Hyperplasia Epidemiology Segmentation:
The CAH market report provides epidemiological analysis for the 2020–2034 study period across the 7MM, segmented into:
- Total Diagnosed Prevalent Cases of Congenital Adrenal Hyperplasia
- Gender-specific Cases of Congenital Adrenal Hyperplasia
- Age-specific Cases of Congenital Adrenal Hyperplasia
- Mutation-based Cases of Congenital Adrenal Hyperplasia
- Type-specific Cases of Congenital Adrenal Hyperplasia
Among mutation-based cases, 21-OHD (CYP21A2 gene mutation) represents a substantially higher prevalence compared to 11-Beta hydroxylase (CYP11B1 gene mutation) and other rarer subtypes.
Download the report to understand which factors are driving Congenital Adrenal Hyperplasia epidemiology trends @ Congenital Adrenal Hyperplasia Epidemiology Forecast
Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on how quickly the therapies used for CAH — whether recently introduced or expected to launch during the study period, 2024–2034 — are being adopted, shaped by the competitive landscape, safety and efficacy data, and order of market entry.
The report’s pipeline coverage tracks therapeutic candidates across Phase I–III development. Crinecerfont (Neurocrine Biosciences), now marketed as CRENESSITY, is an oral CRF1 receptor antagonist already FDA-approved and continuing to expand into younger pediatric populations. Tildacerfont (Spruce Biosciences) is a Phase II CRF-1 antagonist. Atumelnant (Crinetics Pharmaceuticals) is a Phase II oral ACTH receptor antagonist with Orphan Drug Designation. BBP-631 (BridgeBio) is a Phase II AAV gene therapy delivering a functional CYP21A2 gene directly to the adrenal gland, aiming to restore natural cortisol and aldosterone production. Lu AG13909 (H. Lundbeck A/S) is a Phase I anti-ACTH monoclonal antibody. The report also details collaborations, acquisitions, licensing arrangements, and patent activity relevant to these emerging therapies.
Congenital Adrenal Hyperplasia Key Companies
- Neurocrine Biosciences
- Crinetics Pharmaceuticals
- Lundbeck
- Spruce Biosciences
- BridgeBio
- and others
Congenital Adrenal Hyperplasia Key Therapies
- EFMODY — Neurocrine Biosciences
- Crinecerfont (CRENESSITY) — Neurocrine Biosciences
- Tildacerfont — Spruce Biosciences
- ATUMELNANT — Crinetics Pharmaceuticals
- BBP-631 — BridgeBio
- Lu AG13909 — H. Lundbeck A/S
- and others
Discover more about the therapies positioned to shape the Congenital Adrenal Hyperplasia treatment landscape @ Congenital Adrenal Hyperplasia Treatment Landscape
Congenital Adrenal Hyperplasia Market Drivers
- Wider newborn screening programs and greater clinician awareness are increasing early detection of both classic and non-classic CAH, expanding the diagnosed patient pool and driving demand for acute and long-term therapies.
- Improved biochemical assays, second-tier testing to reduce false positives, and more accessible genetic testing are supporting more personalized therapy choices and greater utilization of specialty drugs.
- A strong pipeline of novel therapeutics — including gene therapies like BBP-631 and CRF1/ACTH-targeted agents like crinecerfont, tildacerfont, and atumelnant — is expected to offer potentially disease-modifying options that improve patient outcomes.
- Government support and orphan drug incentives for rare diseases are encouraging continued research and development investment in CAH.
- Expanding healthcare infrastructure and improved access to specialized endocrinology care are enabling more timely diagnosis and long-term disease management.
Congenital Adrenal Hyperplasia Market Barriers
- Current glucocorticoid-based therapy manages symptoms but carries significant side-effect burden from high steroid dosages, including risks of early adiposity rebound and obesity in pediatric patients.
- Despite growing pipeline activity, comprehensive treatment guidelines for adolescents and adults with 21-hydroxylase deficiency remain an area of significant unmet need.
- The transition from pediatric to adult care requires careful, structured coordination between endocrinologists to protect long-term outcomes such as fertility and psychosocial wellbeing, and gaps in this transition process persist.
Scope of the Congenital Adrenal Hyperplasia Market Report
- Study Period: 2020–2034
- Forecast Period: 2024–2034
- Coverage: 7MM
- Key Congenital Adrenal Hyperplasia Companies: Neurocrine Biosciences, Crinetics Pharmaceuticals, Lundbeck, Spruce Biosciences, BridgeBio, and others
- Congenital Adrenal Hyperplasia Therapeutic Assessment: CAH current marketed and emerging therapies
- Congenital Adrenal Hyperplasia Market Dynamics: CAH market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Market entry strategies
- Congenital Adrenal Hyperplasia Unmet Needs, KOL’s Views, Analyst’s Views, Congenital Adrenal Hyperplasia Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.
Contact Information
Kanishk
